2 completed, 1 unknown. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow CellabMED: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) YYB-103 - Recurrent Malignant Glioma | Phase 1 | Unknown | CellabMED | 18 | 2022-07-18 | 2023-01-06 |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients YYB101 - Colorectal Cancer Metastatic, Colorectal Cancer Recurrent | Phase 1 / Phase 2 | Completed | CellabMED | 35 | 2019-08-09 | 2022-11-14 |
| Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy YYB101 - Solid Tumors | Phase 1 | Completed | CellabMED | 39 | 2015-07-13 | 2021-05-13 |
Glioma (1)
monoclonal antibody YYB-101 (2)
South Korea (3)
Garam Im (1) · Hong SungHee, MS (1) · Hoonkyo Kim, Ph.D (1) · Kim Jung Yong, MD, Ph.D (1)